Dr. Siegel on Pomalidomide in Lenalidomide-Refractory Patients With Myeloma
January 09, 2019
David M. Siegel, M.D., Ph.D., chief of myeloma, John Theurer Cancer Center, professor of medicine, Hackensack Meridian Health, discusses the feasibility of using pomalidomide to treat patients with myeloma who have become refractory to lenalidomide.
READ FULL ARTICLE ON ONCLIV.COM